Clinical Trials

Voclosporin is in Phase 3 Clinical Development for Lupus Nephritis

Voclosporin, an investigational compound, has a synergistic, dual mechanism of action that may have the potential to improve near and long-term outcomes in patients with LN when added to mycophenolate mofetil (MMF) and low oral corticosteroids.

Aurinia has completed a proof of concept study and a Phase 2 clinical study with voclosporin for the treatment of lupus nephritis.

AURORA - Phase 3

A Phase 3 global placebo-controlled clinical trial to assess voclosporin for the treatment of active lupus nephritis is ongoing. This study is closed for recruitment.

For more information about this clinical trial, please email clinicaltrials@auriniapharma.com.

AURA-LV - Phase 2

AURA-LV is the first global clinical trial in active LN to meet its primary endpoint.

We successfully completed AURA-LV (AURA), a global placebo controlled Phase 2 study that aimed to evaluate whether voclosporin added to mycophenolate mofetil (MMF) could increase speed of remission and overall remission rates in the presence of low doses of steroids.

AURION - Proof of Concept

We successfully completed AURION, an exploratory proof of concept study assessing the short term predictors of remission of Voclosporin 23.7mg BID in combination with standard of care in patients with active lupus nephritis. Patients were evaluated at the exploratory endpoint (8 weeks), then again at 24 weeks and at the end of the study, at 48 weeks.

Voclosporin is in Phase 2 Clinical Development for FSGS

Voclosporin is also being evaluated for the treatment of focal segmental glomerularsclerosis, or FSGS. A Phase 2, open-label study, evaluating voclosporin as a first-line treatment for FSGS has been initiated and is currently recruiting patients. For more information, please email clinicaltrials@auriniapharma.com .

Voclosporin is in Phase 2 Clinical Development for Dry Eye

Additionally, a proprietary, topical formulation of voclosporin, VOS (voclosporin ophthalmic solution), is being evaluated for the treatment of dry eye syndrome (DES)/dry eye disease (DED)/keratoconjuctivitis sicca (KCS). A Phase 2 randomized, active-controlled, parallel-group study of the ocular tolerability of VOS in DES patients has been initiated and is currently recruiting patients. For more information, please email clinicaltrials@auriniapharma.com .

Clinical Trials

What's a clinical trial?